פולבסטרנט סנדוז - Fulvestrant sandoz: הבדלים בין גרסאות

MonotherapyFulvestrant Sandoz® is indicated for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:- Not previously treated with endocrine therapy, or - With disease relapse on or after adjuvant endocrine therapy; or - disease progression on endocrine therapyCombination Therapy with PalbociclibFulvestrant Sandoz® is indicated for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy.